Taiwan-based Adimmune Corporation (ADIM) to conduct its 2nd phase of COVID-19 vaccine human trials in Indonesia, the firm announced.
The human trials was approved by Indonesian food and drug regulator BPOM and will be carried out by scientists from Gadjah Mada University in Sleman Regency, Java.
The company aims to tap the Muslim-based market with halal certification. Indonesia has the world’s largest Muslim population.
The trial will involve 240 participants and determine the dose number and efficacy of the vaccine against the coronavirus.
Adimmune said that the Indonesian trials would determine the optimal dosage for its vaccine to generate adequate protection against COVID-19 variants and prove its efficacy.
Adimmune’s clinical trials in Indonesia would give participants three doses, adding that the company’s phase 2 trial would require more time and results are expected to be released next year.
Adimmune said it expects to complete the phase 1 and 2 trials early next year, but it would not seek emergency use authorization (EUA) upon completion.
No comments:
Post a Comment